"Q1 started strong with fourteen $50M+ offerings in the initial six weeks. However, escalating concerns over tariffs, recession fears, sticky inflation, and budget talks led to market volatility, delaying hopes for a stabilized IPO market. Despite these challenges, Q1 concluded with CoreWeave entering the public market, and we are optimistic that Q2 will bring the clarity and stability needed for a normalized IPO market." Craig Clay, President of Global Capital Markets, DFIN
Congratulations to the 52 companies in Q1 that made their public debut via a traditional IPO, raising ~$8.4 billion, and the 10 that made their public debut via a SPAC merger. Special congratulations to our clients:
- Aardvark Therapeutics
- Beta Bionics
- CoreWeave
- Flowco
- Infinity Natural Resources
- Karman Space & Defense
- Kestra Medical
- Maze Therapeutics
- Metsera
- SailPoint
- Sionna Therapeutics
- Titan America
- Venture Global
